Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: Predictors of tumor shrinkage

Endocrine Journal

Volumn 53, Issue 1, 2006, Pages 125-132

  Oshino, Satoru ^a   Saitoh, Youichi ^a,d   Kasayama, Soji ^a   Arita, Norio ^b   Ohnishi, Takanori ^c   Kohara, Haruhiko ^a   Izumoto, Shuichi ^a   Yoshimine, Toshiki ^a  

^a OSAKA UNIVERSITY   (Japan)

^b HYOGO COLLEGE OF MEDICINE   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acromegaly; Bromocriptine; Octreotide; Tumor shrinkage

Indexed keywords

BROMOCRIPTINE; BROMOCRIPTINE MESILATE; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C;

ADULT; AGED; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTION; PREOPERATIVE TREATMENT; RETROSPECTIVE STUDY; REVIEW; TRANSSPHENOIDAL SURGERY; TREATMENT OUTCOME; TUMOR VOLUME;

ACROMEGALY; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GROWTH HORMONE; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PATIENT SELECTION; PITUITARY NEOPLASMS; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; TIME FACTORS; TUMOR BURDEN;

EID: 33645009542     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.53.125     Document Type: Review

References (44)

1. Melmed S (1990) Acromegaly. N Engl J Med 322: 966-977.
2. Merza Z (2003) Modern treatment of acromegaly. Postgrad Med J 79: 189-193.
3. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85: 526-529.
4. Arita K, Kurisu K, Tominaga A, Eguchi K, Iida K, Uozumi T, Kasagi F (2003) Mortality in 154 surgically treated patients with acromegaly - a 10-year followup survey. Endocr J 50: 163-172.
5. Ikeda H, Jokura H, Yoshimoto T (2001) Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma. J Neurosurg 95: 285-291.
6. Kreutzer J, Vance ML, Lopes MB, Laws ER Jr (2001) Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. J Clin Endocrinol Metab 86: 4072-4077.
7. De P, Rees DA, Davies N, John R, Neal J, Mills RG, Vafidis J, Davies JS, Scanlon MF (2003) Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 88: 3567-3572.
8. Freda PU (2003) How effective are current therapies for acromegaly? Growth Horm IGF Res 13 (Suppl A) S144-S151.
9. Barkan AL, Lloyd RV, Chandler WF, Hatfield MK, Gebarski SS, Kelch RP, Beitins IZ (1988) Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab 67: 1040-1048.
10. Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ (1994) Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab 79: 1416-1423.
11. Wasko R, Ruchala M, Sawicka J, Kotwicka M, Liebert W, Sowinski J (2000) Short-term pre-surgical treatment with somatostatin analogues, octreotide and lanreotide, in acromegaly. J Endocrinol Invest 23: 12-18.
12. Stevenaert A, Harris AG, Kovacs K, Beckers A (1992) Presurgical octreotide treatment in acromegaly. Metabolism 41: 51-58.
13. Stevenaert A, Beckers A (1996) Presurgical octreotide: treatment in acromegaly. Metabolism 45: 72-74.
14. Tachibana E, Saito K, Yoshida J (1999) Preoperative short-term administration of octreotide for facilitating transsphenoidal removal of invasive growth hormone-secreting macroadenomas. Neurol Med Chir (Tokyo) 39: 496-499; discussion 499-501.
15. Abe T, Ludecke DK (2001) Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre. Eur J Endocrinol 145: 137-145.
16. Colao A, Ferone D, Cappabianca P, del Basso De Caro ML, Marzullo P, Monticelli A, Alfieri A, Merola B, Cali A, de Divitiis E, Lombardi G (1997) Effect of octreotide pretreatment on surgical outcome in acromegaly. J Clin Endocrinol Metab 82: 3308-3314.
17. Saitoh Y, Arita N, Ohnishi T, Ekramullah S, Takemura K, Hayakawa T (1997) Absence of apoptosis in somatotropinomas treated with octreotide. Acta Neurochir (Wien) 139: 851-856.
18. Kristof RA, Stoffel-Wagner B, Klingmuller D, Schramm J (1999) Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study. Acta Neurochir (Wien) 141: 399-405.
19. Biermasz NR, van Dulken H, Roelfsema F (1999) Direct postoperative and follow-up results of transsphenoidal surgery in 19 acromegalic patients pretreated with octreotide compared to those in untreated matched controls. J Clin Endocrinol Metab 84: 3551-3355.
20. Lucas-Morante T, Garcia-Uria J, Estrada J, Saucedo G, Cabello A, Alcaniz J, Barcelo B (1994) Treatment of invasive growth hormone pituitary adenomas with long-acting somatostatin analog SMS 201-995 before transsphenoidal surgery. J Neurosurg 81: 10-14.
21. Hasegawa Y, Hasegawa T, Fujii K, Konii H, Anzo M, Aso T, Kotoh S, Tsuchiya Y (1995) Clinical information on serum IGFBP-3 levels and IGFBP-3 proteolytic activity in childhood. Prog Growth Factor Res 6: 457-463.
22. Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33: 610-617; discussion 617-618.
23. Lundin P, Pedersen F (1992) Volume of pituitary macroadenomas: assessment by MRI. J Comput Assist Tomogr 16: 519-528.
24. Melmed S, Vance ML, Barkan AL, Bengtsson BA, Kleinberg D, Klibanski A, Trainer PJ (2002) Current status and future opportunities for controlling acromegaly. Pituitary 5: 185-196.
25. Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Ho K, Kleinberg D, Lamberts S, Laws E, Lombardi G, Vance ML, Werder KV, Wass J, Giustina A (2002) Guidelines for acromegaly management. J Clin Endocrinol Metab 87: 4054-4058.
26. Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Longterm effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86: 2779-2786.
27. Losa M, Mortini P, Giovanelli M (1999) Is presurgical treatment with somatostatin analogs necessary in acromegalic patients? J Endocrinol Invest 22: 871-873.
28. Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83: 3034-3040.
29. Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, Cirillo S, Merola B, Lombardi G (1997) Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab 82: 518-523.
30. Stewart PM (2000) Current therapy for acromegaly. Trends Endocrinol Metab 11: 128-132.
31. Racine MS, Barkan AL (2003) Somatostatin analogs in medical treatment of acromegaly. Endocrine 20: 271-278.
32. Ezzat S, Horvath E, Harris AG, Kovacs K (1994) Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab 79: 113-118.
33. Reubi JC, Landolt AM (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab 68: 844-850.
34. Park C, Yang I, Woo J, Kim S, Kim J, Kim Y, Sohn S, Kim E, Lee M, Park H, Jung J, Park S (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to octreotide. Endocr J 51: 227-236.
35. Plockinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ (1997) Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume-and hormone-response to ocreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 136: 369-376.
36. Yang IM, Woo JT, Kim SW, Kim JW, Kim YS, Choi YK (1995) Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Clin Endocrinol (Oxf) 42: 295-301.
37. Lamberts SW, Zweens M, Verschoor L, del Pozo E (1986) A comparison among the growth hormone-lowering effects in acromegaly of the somatostatin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab 63: 16-19.
38. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC (2000) Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288: 154-157.
39. Lu JQ, Stoessl AJ (2002) Somatostatin modulates the behavioral effects of dopamine receptor activation in parkinsonian rats. Neuroscience 112: 261-266.
40. Izquierdo-Claros RM, del Boyano-Adanez M, Arilla-Ferreiro E (2000) Activation of D1 and D2 dopamine receptors increases the activity of the somatostatin receptor-effector system in the rat frontoparietal cortex. J Neurosci Res 62: 91-98.
41. Rodriguez-Sanchez MN, Puebla L, Lopez-Sanudo S, Rodriguez-Martin E, Martin-Espinosa A, Rodriguez-Pena MS, Juarranz MG, Arilla E (1997) Dopamine enhances somatostatin receptor-mediated inhibition of adenylate cyclase in rat striatum and hippocampus. J Neurosci Res 48: 238-248.
42. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, Melmed S (2003) Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 88: 5414-5421.
43. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P (2002) Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endocrinol Metab 87: 5545-5552.
44. Kurosaki M, Luedecke DK, Abe T (2003) Effectiveness of secondary transnasal surgery in GH-secreting pituitary macroadenomas. Endocr J 50: 635-642.